Bio-Rad Laboratories reported signs of stabilization and growth for 2025 after challenges from supply chain issues and a biopharma downturn. The company anticipates flat to 1% revenue growth supported by improvements in process chromatography and digital PCR product lines. Executives highlighted durable consumables sales despite academic funding constraints and easing trade tensions affecting the diagnostics sector. Recent acquisitions and product launches contribute to a cautiously optimistic outlook.